Clinical InvestigationPrevention and RehabilitationEfficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
Section snippets
Study design
This was a multicenter (61 centers), randomized, double-blind, placebo-controlled, parallel-group dose-ranging study to assess the efficacy, safety, and tolerability of anacetrapib, administered as monotherapy or with atorvastatin 20 mg (Pfizer Pharmaceuticals, Ltd, New York, NY), in patients with primary hypercholesterolemia or mixed hyperlipidemia. After screening and placebo run-in, eligible patients were randomized via an interactive voice response system equally to one of 10 groups: 5
Baseline demographics and efficacy variables
Baseline demographic characteristics and efficacy variables of the randomized patients (n = 589) were similar across the 10 treatment groups (Table I; expanded Table I in Appendix A, available online). Overall, 53.8% of patients had low HDL-C levels (≤44 mg/dL in men and ≤54 mg/dL in women). The median baseline LDL-C for the overall population was 140.1 mg/dL. Median baseline aldosterone levels were 7.5, 0.0, and 8.8 ng/dL in the anacetrapib 40-, 150-, and 300-mg + atorvastatin 20-mg groups,
Discussion
Anacetrapib, a potent CETP inhibitor, was associated with substantial and significant dose-dependent decreases in LDL-C and increases in HDL-C, with no demonstrable increase in blood pressure. The maximal pharmacodynamic lipid effect resulted in decreases in LDL-C and apo B of ∼40% and ∼30%, respectively, and increases in HDL-C and apo A-I of 139% and 47%, respectively. At the top doses of anacetrapib (150 and 300 mg), the maximal reductions in LDL-C and apo B were similar to those with
References (25)
Plasma cholesteryl ester transfer protein
J Lipid Res
(1993)- et al.
Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia
Atherosclerosis
(1985) - et al.
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels
J Am Coll Cardiol
(2006) - et al.
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin
J Am Coll Cardiol
(2006) - et al.
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial
Lancet
(2007) - et al.
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies
Lancet
(2007) - et al.
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
J Am Coll Cardiol
(1986) - et al.
Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits
J Biol Chem
(1998) - et al.
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits
J Lipid Res
(2007) - et al.
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk
JAMA
(2008)
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis
Arterioscler Thromb Vasc Biol
Effects of torcetrapib in patients at high risk for coronary events
N Engl J Med
Cited by (232)
Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'Athérosclérose (NSFA)
2021, Archives of Cardiovascular DiseasesCitation Excerpt :Cholesteryl ester transfer protein (CETP) inhibitors have shown promising Lp(a)-lowering effects, involving a decrease in hepatic apo(a) production rate [160]. In the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) study, anacetrapib given in combination with statins decreased Lp(a) by 17% [161]. However, CETP inhibitors were either without effect or led to a minor reduction in Lp(a) concentrations [162], and they are not approved for clinical use.
Cholesteryl ester transfer protein inhibitors in precision medicine
2020, Clinica Chimica ActaEvacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes
2019, AtherosclerosisCitation Excerpt :This relationship is thought to be largely mediated by the ability of HDL to transport excess cholesterol from peripheral tissues back to the liver for excretion, a process known as reverse cholesterol transport [2]. Potent cholesteryl ester transfer protein (CETP) inhibitors, like torcetrapib, evacetrapib and anacetrapib, significantly increase HDL-C and decrease LDL-C levels, as monotherapy and in combination with statins [3–6]. However, except anacetrapib [7], these lipoprotein changes have not resulted in reduction of major cardiovascular events (MACE) [8–10].
Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week
2019, Journal of the American College of CardiologyCholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis
2019, Progress in Lipid ResearchEvolocumab Lowers Low-Density-Lipoprotein Cholesterol and Lipoprotein (A) Levels in Nephrotic Syndrome
2018, AACE Clinical Case Reports
Registered Clinical Trial No.: NCT00325455.